ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Ascendis Pharma A/S
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 11, 2026
$229.95+4.70 (+2.09%)
Close on Oct 19, 2026
Ascendis Pharma A/S revenue by segment
By business segment
By product or service
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | €265.47M | €209.08M | – | – | €108.34M | €73.63M | – | – | – | – | – | – | 78.2% | +145.0% |
| Europe [member] | €49.67M | €36.32M | €38.34M | €33.38M | €27.89M | €21.33M | €108.54M | €8.15M | €5.08M | €1.57M | €488.00K | €381.00K | 14.6% | +78.1% |
| Rest of World [member] | €24.14M | €1.21M | €6.03M | €19.12M | €21.81M | €5.99M | €3.10M | €924.00K | €1.52M | €1.65M | €72.60M | €419.00K | 7.1% | +10.7% |
| Denmark | €3.60M | €4.50M | €3.80M | €4.10M | €2.60M | €2.40M | €95.40M | €0 | €0 | €0 | – | – | 1.1% | +38.5% |
| North America [member] | – | – | – | €161.13M | €108.45M | €73.69M | €62.39M | €48.76M | €29.39M | €92.68M | €64.62M | €47.23M | – | – |
| Asia [Member] | – | – | – | – | – | – | – | – | €1.52M | €1.65M | €72.60M | €419.00K | – | – |
From the segment and revenue-disaggregation notes of Ascendis Pharma A/S's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.